MedPath

Oxaliplatin vs Cisplatin in Chemoradiotherapy of Head and Neck Cancer

Phase 3
Completed
Conditions
Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
Registration Number
CTRI/2019/01/017198
Lead Sponsor
AIIMS Rishikesh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
70
Inclusion Criteria

1.Histologically confirmed locally advanced head and neck squamous cell cancers.

2.Stage III-IVB by AJCC Cancer Staging Manual Eight Edition, 2017.

3.Primary tumour sites in oral cavity, oropharynx, hypopharynx and larynx.

4.Age >18 years and <70 years.

5.Eastern Cooperative Oncology Group (ECOG) performance status of <=2.

6.Haemoglobin > 10g/L.

7.Total Leucocyte count > 4,000/cumm.

8.Platelet count > 1,00,000/cumm.

9.Bilirubin <1.5mg/dL, SGOT and SGPT < 3Ã? upper limit.

10.Normal Serum creatinine and Blood Urea.

11.Patients who had not received prior chemotherapy and/or radiotherapy.

Exclusion Criteria

1.Synchronous malignancy.

2.Previously diseased salivary gland.

3.Patients with history of neuropathy e.g. Diabetic neuropathy

4.Patients with Congestive cardiac failure.

5.Patients with uncontrolled hypertension.

6.Patients not willing for concurrent chemoradiotherapy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
% of tumour responseTimepoint: 3 months and 6 months
Secondary Outcome Measures
NameTimeMethod
Compliance of concurrent oxaliplatin with radiotherapy in locally advanced non-nasopharyngeal head and neck cancer.Timepoint: During treatment;To compare disease control at 6 months with concurrent chemoradiotherapy using oxaliplatin versus concurrent chemoradiotherapy using cisplatin in locally advanced non-nasopharyngeal head and neck cancer.Timepoint: 6 months;To compare the toxicity profile of concurrent chemoradiotherapy using oxaliplatin versus concurrent chemoradiotherapy using cisplatin in locally advanced non-nasopharyngeal head and neck cancers.Timepoint: Weekly review during treatment. <br/ ><br>
© Copyright 2025. All Rights Reserved by MedPath